Silicon to Blockchain: ARK's Strategic Pivot in Disruptive Tech

Generated by AI AgentCoin WorldReviewed byAInvest News Editorial Team
Friday, Nov 14, 2025 8:26 am ET1min read
Speaker 1
Speaker 2
AI Podcast:Your News, Now Playing
Aime RobotAime Summary

- ARK Invest sold $22.5M

shares on Nov 13, 2025, reallocating to crypto firms and Bitmine, signaling a strategic shift toward and .

- The firm divested over $29M in

, , and while boosting crypto exposure via 188K Circle shares and 242K Bitmine shares amid sector declines.

- Biotech investments in Beam and

extended a weeklong accumulation pattern, reflecting ARK's focus on gene-editing and pharmaceutical innovation.

- Total trading activity exceeded $70M, emphasizing high-growth bets on decentralized finance and blockchain infrastructure despite AMD's AI chip market challenges.

Cathie Wood's

Invest on November 13, 2025, exiting a $22.5 million position in Advanced Micro Devices (AMD) while allocating $26 million to crypto-related firms Internet Group and Technologies, according to trading disclosures. The moves reflect a strategic pivot away from semiconductor stocks and into digital infrastructure and biotech sectors, on disruptive technologies despite broader market volatility.

The

sale involved 87,051 shares transacted through the , after the chipmaker's 2025 Analyst Day on November 11. AMD shares closed at $247.96 on November 13, down 4% from their post-event peak. ARK also ($15.6 million), Regeneron ($8.2 million), and Salesforce ($5.4 million), totaling over $29 million in divestments.

Concurrently, ARK

by purchasing 188,941 Circle shares for $16.3 million across three ETFs, marking the second consecutive day of buying.
Circle, issuer of the stablecoin, to $82.34 on the day of the purchase. The firm also for $9.8 million, expanding its stake in the crypto mining infrastructure provider. Bitmine's stock had to $36.57, aligning with broader sector weakness.

Biotech investments included $3.1 million in Beam Therapeutics and $1.2 million in Recursion Pharmaceuticals,

in gene-editing and pharmaceutical innovation. The total trading activity exceeded $70 million, underscoring ARK's focus on high-growth, capital-efficient plays.

ARK's Circle purchases highlight confidence in stablecoin infrastructure,

a potential native token for its Arc blockchain network. Meanwhile, Bitmine's role in supporting crypto operations aligns with ARK's thesis on institutional adoption of blockchain technology.

The trades come as AMD faces heightened competition in AI chip markets,

35% annual revenue growth over the next three to five years. Despite AMD's 97% year-to-date stock surge, ARK's exit suggests profit-taking amid speculative bets on next-generation rivals like Nvidia's MI400 chips.

ARK's strategy mirrors broader institutional trends, including David Tepper's Appaloosa Management,

in Q3 2025 while exiting Intel. However, ARK's focus on crypto infrastructure diverges from traditional tech holdings, to decentralized finance and digital asset networks.

Comments



Add a public comment...
No comments

No comments yet